Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News ArQule Inc. ARQL

Healthcare Biotechnology
Arqule Inc is a biopharmaceutical company, engaged in the research and development of therapeutics to treat cancers and rare diseases. The objective of the company is to discover, develop and commercialize novel small molecule drugs in areas of high unmet need that will dramatically extend and improve the lives of the patients. These drugs focus on the biological pathways implicated in a range... see more

Recent & Breaking News (NDAQ:ARQL)

Basilea licenses late-stage oncology drug candidate derazantinib from ArQule

GlobeNewswire April 17, 2018

23 Stocks Moving In Monday's Pre-Market Session

Benzinga.com  April 16, 2018

The Week Ahead In Biotech: PDUFA Dates, IPOs And More

Benzinga.com  April 13, 2018

40 Biggest Movers From Yesterday

Benzinga.com  April 10, 2018

6 Stocks Moving In Monday's After-Hours Session

Benzinga.com  April 9, 2018

41 Biggest Movers From Yesterday

Benzinga.com  April 3, 2018

Recent Analysis Shows Energy Fuels, Vipshop, Tenaris S.A, ArQule, Teekay Offshore Partners, and Chicago Bridge & Iron Company N.V Market Influences — Renewed Outlook, Key Drivers of Growth

GlobeNewswire March 27, 2018

ArQule to Present at the 17th Annual Needham Healthcare Conference on March 27, 2018

Business Wire March 20, 2018

ArQule to Present Data at the 2018 American Association for Cancer Research (AACR) Annual Meeting

Business Wire March 15, 2018

ArQule Reports Fourth Quarter and Full Year 2017 Financial Results

Business Wire March 5, 2018

ArQule, Inc. to Host Earnings Call

Accesswire March 5, 2018

ArQule to Present at the 30th Annual Roth Conference on March 12, 2018

Business Wire March 5, 2018

ArQule To Report Fourth Quarter 2017 Financial Results On March 5, 2018

Business Wire February 20, 2018

ArQule to Present at The Leerink Partners 7th Annual Global Healthcare Conference on February 15, 2018

Business Wire February 8, 2018

Roivant Sciences and ArQule Enter into License Agreement for Derazantinib in China

Business Wire February 7, 2018

ArQule Announces Dosing in a Registrational Trial of FGFR Inhibitor, Derazantinib, for Treatment of Intrahepatic Cholangiocarcinoma

Business Wire November 21, 2017

Cancer Immunotherapy Technology Projected to Create Further Growth

PR Newswire November 9, 2017

ArQule, Inc. to Host Earnings Call

Accesswire November 9, 2017

ArQule Reports Third Quarter 2017 Financial Results

Business Wire November 9, 2017

ArQule Announces $9.5 Million Private Placement of Preferred Stock

Business Wire November 8, 2017